Telomir Pharmaceuticals Inc. (Nasdaq: TELO) has announced its participation in the upcoming BIO International Convention 2025 in Boston, Massachusetts, scheduled from June 16-19, 2025. The company plans to engage in BIO One-on-One Partnering™ meetings to explore potential licensing, strategic collaborations, and M&A opportunities. Additionally, Telomir provided updates on its lead candidate, Telomir-1, which is designed to elongate telomeres, regenerate cells, and address key drivers of biological aging. The company is preparing for an Investigational New Drug $(IND.AU)$ submission by the end of the year and anticipates initiating first-in-human clinical trials in the first half of 2026. Telomir also reported preclinical progress in areas such as retinal regeneration, lifespan extension, Type 2 diabetes reversal, and anti-cancer effects. Furthermore, Telomir is launching a rare disease development initiative targeting conditions like Werner's syndrome, Wilson's disease, Progeria, and dysphonia.